- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02807519
Salivary Cytokines as Biomarker for Oral Health (Cytosal)
Salivary Cytokines in Paediatric Oncology Patients and Healthy Persons - A Pilot Study to Investigation of Biomarkers for Oral Health
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Oral complications are common during and after cancer treatment. Oral mucositis typically occurs during or immediately after chemotherapy and may lead to pain, oral and systemic infection, and nutritional compromise. Late effects of oral mucositis as a result of cancer treatment include an increased risk for dental caries, xerostomia and osteonecrosis. It has been recognised, that regular assessment of oral health, prevention and early treatment of oral mucositis decreases early and late complication rates.
Saliva plays a key role in maintaining oral health and reduced salivary flow contributes to acute disorders and long-term sequelae in oral health. Saliva is a complex fluid secreted by the salivary glands and the gingiva. In the last decade numerous studies have investigated immunological biomarkers such as cytokines in saliva samples. These studies included individuals with various oral and systemic diseases including oral cancer, oral caries, autoimmune and endocrine diseases, metabolic syndrome, chronic kidney disease and psychiatric illnesses.
In children, the few studies that have investigated salivary cytokines (sCK) suggest that these are associated with oral health (sCK). For example, one study in 114 healthy adolescent girls aged 11-17 years showed that sCK concentrations were generally not associated with levels in the serum . In addition this study also suggested that the sCK concentrations are age dependent.
However, a number of other studies suggest that sCK may also reflect systemic diseases such as shown in a study including 20 children aged 9-17 with allergies (including asthma, allergic rhinitis and eosinophilic esophagitis) showing that Th-2 cytokines were detectable in sCK.
One study investigating sCK in adult oncology patients showed an association between IL-6 and severity of oral chronic GVHD in survivors of a hematopoietic stem cell transplantation. Therefore determination of sCK concentrations may also be helpful for assessment of GVHD activity and other inflammatory processes in cancer patients. In paediatric oncology patients, to the investigators' knowledge, no study has so far investigated sCK concentrations as markers for oral or systemic health.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Aarau, Switzerland, 5001
- Kinderspital Aarau
-
-
Basel-Stadt
-
Basel, Basel-Stadt, Switzerland
- Schulzahlklinik Basel
-
Basel, Basel-Stadt, Switzerland
- Volkszahnklinik
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- Children with a new haematological/oncological diagnosis
- admitted to the paediatric oncology ward at the UKBB
- who will require radio- and/or chemotherapy.
Healthy children who present at the Schulzahnklinik respectively Volkszahnklinik for a dental prophylaxis
Description
Inclusion Criteria:
- Children with confirmed haematological/oncological disease and necessity for radio-or chemotherapy
- Age > 4 and < 18 years.
Exclusion Criteria:
- patients, who already were treated with radio- or chemotherapy
- patients with current or previous (last 7 days) symptoms of a respiratory infection, rhinitis, bronchitis and tonsillitis
- children with an autoimmune disease
- Use of systemic antibiotics within the last 2 weeks.
- Use of antimicrobial mouth rinsing solution within the last 12 hours,
- any vaccination within the last 48 hours
- known allergy to paraffin.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Oncological patients
Children with confirmed haematological/oncological diagnosis who are admitted to the paediatric oncology ward at the Universitätsspital Beider Basel (UKBB), who will require radio- and/or chemotherapy .
Collection of salivary cytokines will be performed in this group.
|
Collection of the saliva will be done following this procedure: The collection will be done prior to any other dental manipulation.
The test person is sitting with its head tilted slightly forward.
Initially, any saliva present in the mouth must be swallowed or spit out completely.
Then, a paraffin gum is given to the test person.
This paraffin gum must be chewed for minimally 2 and maximally up to 5 minutes.
During the time period that the test person is chewing the paraffin gum, the saliva must be spitted into a cup repeatedly, or the saliva can also be let run passively into the cup.
The amount of saliva is then weighted (1g equivalent to 1 ml) and a saliva flow rate (ml/min) is calculated and noted.
|
Control group
Healthy children which are seen routinely at the Schulzahnklinik/Volkzahnklinik Basel.
Collection of salivary cytokines will be performed in this group.
|
Collection of the saliva will be done following this procedure: The collection will be done prior to any other dental manipulation.
The test person is sitting with its head tilted slightly forward.
Initially, any saliva present in the mouth must be swallowed or spit out completely.
Then, a paraffin gum is given to the test person.
This paraffin gum must be chewed for minimally 2 and maximally up to 5 minutes.
During the time period that the test person is chewing the paraffin gum, the saliva must be spitted into a cup repeatedly, or the saliva can also be let run passively into the cup.
The amount of saliva is then weighted (1g equivalent to 1 ml) and a saliva flow rate (ml/min) is calculated and noted.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
mucositis (clinical oral finding)
Time Frame: 18 months
|
clinical oral finding as mucositis in children with a hematological/oncological disease and healthy control children
|
18 months
|
salivary cytokine (sCK) levels
Time Frame: 18 months
|
salivary cytokine (sCK) levels in children with a hematological/oncological disease and healthy control children
|
18 months
|
aphthous ulcer (clinical oral finding)
Time Frame: 18 months
|
clinical oral finding as aphthous ulcer in children with a hematological/oncological disease and healthy control children
|
18 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Tamara Diesch, Dr., University Children's Hospital of Basel
- Principal Investigator: Cornelia Filippi, Dr., University Centre of Dental Medicine Basel
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
GlaxoSmithKlineRecruitingColonic Neoplasms | Neoplasms, ColonUnited States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompletedUterine Neoplasms | Prostatic Neoplasms | Cervix Neoplasms | Bladder NeoplasmsCanada
-
N.N. Petrov National Medical Research Center of...Active, not recruitingColonic Neoplasms MalignantRussian Federation
-
Peking University First HospitalShengli Oilfield Hospital; The Second Affiliated Hospital of Baotou Medical...Enrolling by invitationRectal Neoplasms MalignantChina
-
Cancer Institute and Hospital, Chinese Academy...CompletedRectal Neoplasms MalignantChina
-
Seattle Children's HospitalSuspendedNeoplasms, Benign | Neoplasms, MalignantUnited States
-
Iuliu Hatieganu University of Medicine and PharmacyInstitutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian...CompletedRetroperitoneal NeoplasmsRomania
-
Pennington Biomedical Research CenterNational Cancer Institute (NCI)RecruitingRectal Neoplasms | Colonic NeoplasmsUnited States
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruitingRadiotherapy | Rectal Neoplasms MalignantChina
Clinical Trials on collection of salivary cytokines
-
Milton S. Hershey Medical CenterRecruiting
-
Institut National de la Santé Et de la Recherche...Commissariat A L'energie AtomiqueActive, not recruiting
-
Hospices Civils de LyonCompleted
-
University of Wisconsin, MadisonCompletedHead and Neck Cancer | XerostomiaUnited States
-
Istanbul Medipol University HospitalCompletedPeriodontitis | Diagnoses DiseaseTurkey
-
IRCCS Centro Neurolesi "Bonino-Pulejo"Regione SiciliaRecruitingAutism Spectrum DisorderItaly
-
University Hospital, Strasbourg, FranceTerminated
-
IRCCS Policlinico S. DonatoRecruiting
-
Yuzuncu Yıl UniversityRecruitingSaliva | Dental CrownTurkey
-
Jena University HospitalGerman Federal Ministry of Education and Research; CytoSorbents, Inc; Thermo... and other collaboratorsCompletedInfective EndocarditisGermany